15ACTIVITIES
1ORGS REPRESENTED
59BILLS
Organizations represented
1Orgs whose LD-2 filings list Nicholas as an active lobbyist, sorted by activity volume.
Bills they file on
59S. 433 mentions
S. 7083 mentions
S. 10403 mentions
S. 10413 mentions
S. 10953 mentions
S. 10963 mentions
S. 10973 mentions
H.R. 8903 mentions
H.R. 15743 mentions
S. 6523 mentions
S. 8323 mentions
S. 8913 mentions
S. 9323 mentions
H.R. 9463 mentions
H.R. 12623 mentions
+ 44 more bills referenced in their activities
Topics in Filings
76Policy topics Nicholas files on across all their LD-2 activities.
Rural Development×6
RESTORE Patent Rights Act×6
Inflation Reduction Act×6
Drug cost and pricing policy×6
Supply chain policy×6
One Big Beautiful Bill Act×6
Skinny Labels×3
Big Savings Act×3
Affordable Prescriptions for Patients Act×3
Stop STALLING Act×3
Preserve Access to Affordable Generics and Biosimilars Act×3
Interagency Patent Coordination and Improvement Act×3
Show all 76 topics (+64 more) ▾
Bayh-Dole march-in rights policy×3
Patent thicket policy×3
Patent use codes policy×3
AI patent policy×3
Patent eligibility policy×3
Post-grant proceeding policy×3
Patent submission policy×3
Modernizing and Ensuring PBM Accountability×3
Give Kids a Chance Act×3
Accountability, and Integrity Now and for the Future×3
User fee issues×3
Vaccine policy×3
Pharmacy Benefit Manager reform×3
Drug importation policy×3
FDA policy×3
Orphan Drug Act×3
Compounding policy×3
Antimicrobial resistance×3
Clinical trial policy×3
Issues 340B drug discount program policy×3
Biosimilar approval and reimbursement policy×3
Artificial intelligence policy×3
Part D redesign and policy×3
Part B policy×3
Medicare rebate policy×3
Center for Medicare and Medicaid Innovation×3
Medicaid rebate policy×3
Biopharmaceutical innovation policy×3
International intellectual property and market access policy×3
Pricing and reimbursement policy×3
WTO TRIPS waiver policy×3
China outbound investment policy×3
Science, and Related Agencies Appropriations Act, 2026×3
FDA Modernization×3
Accelerated approval policy×2
Competition policy×2
Patient assistance program policy×2
Drug shortages policy×2
Insulin policy×2
Medicaid waiver policy×2
Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×2
Res. 566: Providing for consideration of the Senate amendment to the bill×2
Medication Affordability and Patent Integrity Act×2
Biosimilar Red Tape Elimination Act×2
BIOSECURE Act×2
Most Favored Nation×2
Protecting Patients from Deceptive Drug Ads Act×1
Innovation in Pediatric Drugs Act×1
Pandemic preparedness policy×1
Saving Seniors Money on Prescriptions Act×1
Tariff policy×1
Military Construction×1
Expedited Acccess to Biosimilars Act×1
MAPS Act×1
Orphan Cures Act×1
Prescription Information Modernization×1
Stopping Pharmas Ripoffs and Drug Savings For All Act×1
Bipartisan Health Care Act×1
IRA price negotiation expansion policy×1
MAHA Commission Report×1
Make Our Children Healthy Again Competition policy×1
Issues 340B rebate pilot program Patient assistance program policy×1
Biosimilars Access and Affordability Act×1
MVP Act×1
Issue mix
LDA general-issue codes weighted by activity count.
Budget/Appropriations3
Copyright/Patent/Trademark3
Health Issues3
Medicare/Medicaid3
Trade (domestic/foreign)3